Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Legal / IP Policy / Regulatory

China’s Seven Ministries Issue Revised Pharmaceutical Representative Management Measures to Combat Commercial Bribery and Strengthen Industry Oversight

Fineline Cube May 8, 2026
Company Drug

Wuhan YZY Biopharma’s Bispecific Antibody M701 Receives NMPA Acceptance for Review in Malignant Ascites Treatment

Fineline Cube May 8, 2026
Company Drug

Guangdong Zhongsheng Pharma Reports Positive Phase IIb Results for First-in-Class ZSP1601 in Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis Reversal Potential

Fineline Cube May 8, 2026
Company Deals Digital

Zhejiang Dian Diagnostics Partners with Haihe Laboratory to Advance Hematology Diagnostics

Fineline Cube Mar 25, 2024

Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a company based in China, has entered into...

Company Deals

Golden Leaf Med Tec Secures Series D Funding to Advance Hypertension and Diabetes Treatments

Fineline Cube Mar 25, 2024

Shanghai Golden Leaf Med Tec Co., Ltd, a specialist in interventional treatments based in China,...

Company Deals Drug

Joincare Pharmaceuticals Secures Rights to Bayer’s Respiratory Drug in China

Fineline Cube Mar 25, 2024

Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a Chinese pharmaceutical company, has announced a...

Company Deals

AriBio Expands Alzheimer’s Drug AR1001 Licensing Deal with Samjin to Include China

Fineline Cube Mar 25, 2024

AriBio Co., Ltd, a South Korea-based pharmaceutical company, has announced an expansion of its previous...

Company Deals

Sino Biological Partners with Rapid Novor to Market mAb Sequencing Services Across Asia

Fineline Cube Mar 22, 2024

Sino Biological Inc. (SHE: 301047), a leading supplier of reagents based in China, has announced...

Company Drug

Lynk Pharmaceuticals Doses First Patient in Phase III Trial for Atopic Dermatitis Treatment

Fineline Cube Mar 22, 2024

Lynk Pharmaceuticals Co., Ltd, based in China, has announced the dosing of the first patient...

Company Drug

HutchMed Launches Phase II/III Study for Sovleplenib in Autoimmune Hemolytic Anemia

Fineline Cube Mar 22, 2024

HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced the initiation of the Phase II/III...

Company Drug

NeuExcell Therapeutics Doses First Patient in Groundbreaking Clinical Trial for NeuroD1 Gene Therapy

Fineline Cube Mar 22, 2024

NeuExcell Therapeutics, a Shanghai-based developer of in vivo neural regenerative therapies, has announced the first...

Company Deals

Astra Biotech Raises Tens of Millions in Pre-Series B Funding to Expand Diagnostic Capabilities

Fineline Cube Mar 22, 2024

Astra Biotech, a developer of single molecule immunodiagnostic technology based in Suzhou, has reportedly raised...

Company Deals

Horimed Secures Tens of Millions in Financing to Advance OCT Imaging Technologies

Fineline Cube Mar 22, 2024

Horimed, a Tianjin-based manufacturer of OCT imaging equipment, has reportedly raised “tens of millions” of...

Company Deals

Beijing Varnotech Biopharm Secures RMB 600 Million in Series B Funding for Vaccine Development

Fineline Cube Mar 22, 2024

Beijing Varnotech Biopharm Ltd, a China-based specialist in human vaccines, has successfully raised RMB 600...

Company Deals

PoreSpect Secures Tens of Millions in Angel Funding Led by Forcefield Ventures

Fineline Cube Mar 22, 2024

PoreSpect, a Guangdong-based manufacturer of devices and consumables, has reportedly secured “tens of millions” of...

Company Medical Device

Intuitive Surgical’s Ion Robotic System Gains Regulatory Approval in China

Fineline Cube Mar 22, 2024

Intuitive Surgical (NASDAQ: ISRG), a leading medical robotics firm based in the US, has announced...

Company

Henlius Biotech Posts 67.8% YOY Revenue Growth and First Annual Profit in 2023 Financials

Fineline Cube Mar 22, 2024

Shanghai Henlius Biotech Inc., (HKG: 2696) has released its financial results for 2023, reporting revenues...

Company

Bayer Eliminates C-Level Roles in Restructuring Efforts to Boost Profitability

Fineline Cube Mar 22, 2024

Germany’s Bayer (ETR: BAYN) has taken significant steps in its restructuring efforts by eliminating 8...

Company Deals Digital

Baidu Health Partners with Yibang to Enhance Operations for Brick-and-Mortar Pharmacies

Fineline Cube Mar 21, 2024

Baidu Health has entered into a strategic partnership with Shanghai Yibang Medicine Information Technology Co.,...

Company Deals

Edan Instruments Partners with Global Health Labs to Develop AI-Enhanced Handheld Ultrasound

Fineline Cube Mar 21, 2024

Shenzhen-based Edan Instruments Inc. has forged a strategic partnership with Global Health Labs Inc. to...

Company Drug

FDA Grants Accelerated Approval for Takeda’s Iclusig in Newly Diagnosed Ph+ ALL

Fineline Cube Mar 21, 2024

The U.S. Food and Drug Administration (FDA) has granted accelerated indication extension approval to Japan’s...

Policy / Regulatory

China Unveils Action Plan to Boost Foreign Investment and Open Economy Further

Fineline Cube Mar 21, 2024

The State Council of China has unveiled an ambitious “Action Plan to Promote the High-Level...

Company

Simcere Pharmaceutical Reports 4.5% Revenue Growth in 2023 Amid Shifts in Profitability

Fineline Cube Mar 21, 2024

Simcere Pharmaceutical Group (HKG: 2096), based in China, has released its 2023 financial performance report,...

Posts pagination

1 … 381 382 383 … 661

Recent updates

  • Wuhan YZY Biopharma’s Bispecific Antibody M701 Receives NMPA Acceptance for Review in Malignant Ascites Treatment
  • Guangdong Zhongsheng Pharma Reports Positive Phase IIb Results for First-in-Class ZSP1601 in Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis Reversal Potential
  • Suzhou Zelgen Biopharmaceuticals Achieves Primary Endpoint in Phase III Trial for Zesuning in Thyroid Cancer Ablation Therapy
  • Jiangsu Lianhuan Pharma Reports Positive Phase III Results for LH-1801 SGLT-2 Inhibitor in Type 2 Diabetes Treatment
  • China’s Seven Ministries Issue Revised Pharmaceutical Representative Management Measures to Combat Commercial Bribery and Strengthen Industry Oversight
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Wuhan YZY Biopharma’s Bispecific Antibody M701 Receives NMPA Acceptance for Review in Malignant Ascites Treatment

Company Drug

Guangdong Zhongsheng Pharma Reports Positive Phase IIb Results for First-in-Class ZSP1601 in Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis Reversal Potential

Company Drug

Suzhou Zelgen Biopharmaceuticals Achieves Primary Endpoint in Phase III Trial for Zesuning in Thyroid Cancer Ablation Therapy

Company Drug

Jiangsu Lianhuan Pharma Reports Positive Phase III Results for LH-1801 SGLT-2 Inhibitor in Type 2 Diabetes Treatment

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.